Antibodies to ß(2) glycoprotein I (IgG and IgM isotypes) have recently been added to the laboratory criteria of the revised antiphospholipid syndrome classification criteria. We investigated whether IgM anti-ß(2)-glycoprotein I (anti-ß(2)-GPI) is associated with clinical manifestations of systemic lupus erythematosus (SLE).